Opportunity Information: Apply for PA 16 426
This National Institutes of Health (NIH) grant opportunity (Funding Opportunity Number PA-16-426) is an R01 research project grant focused on cancers that occur in people living with HIV or AIDS, with particular emphasis on non-AIDS-defining malignancies. The central goal is to push the science forward on why these cancers occur, how they develop and progress, how they can be detected and diagnosed more effectively, and how they can be treated in the context of HIV infection. The announcement highlights that non-AIDS-defining cancers have become a leading cause of death among HIV-infected individuals, which makes understanding and addressing these malignancies an urgent public health need.
The research scope is broad and encourages projects that address high or medium priority AIDS-related cancer questions. Examples of encouraged topic areas include identifying etiologic factors and cofactors (such as viral coinfections, behavioral or environmental exposures, and treatment-related influences), clarifying immunopathogenesis (how HIV-associated immune dysfunction and immune activation contribute to cancer initiation and progression), improving diagnosis and clinical characterization of malignancies in HIV-positive populations, and studying the consequences of these cancers for patient outcomes and survivorship. The FOA supports work across both non-AIDS-defining cancers and traditional AIDS-defining cancers, as long as the work directly advances knowledge relevant to malignancies in people with underlying HIV infection.
The program is listed under CFDA numbers 93.121 and 93.393 and falls within the Education and Health funding activity categories. The funding instrument is a discretionary grant mechanism (R01), meaning it is intended for substantial, hypothesis-driven research projects that can produce rigorous, generalizable findings. While the source text does not provide an award ceiling or the expected number of awards, the R01 mechanism typically supports multi-year research efforts with clearly defined aims, a strong scientific premise, and an approach appropriate to the complexity of cancer and HIV comorbidity research.
Eligibility is intentionally expansive to encourage participation from a wide range of organizations capable of conducting biomedical, clinical, behavioral, and population-based research. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses); small businesses; and other entities. The FOA also specifically calls out additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations). This broad eligibility signals an interest in diverse perspectives, varied research settings, and studies that may involve international populations or cross-regional collaborations where HIV-associated cancer burdens are significant.
Key administrative details include an original closing date of 2019-09-07 and a creation date of 2016-09-07, indicating the FOA was issued to support continuing research efforts during that period. Overall, the opportunity is designed for investigators and institutions seeking to address the changing cancer landscape in the HIV population, especially the rising importance of non-AIDS-defining malignancies, by generating evidence that can improve prevention strategies, diagnostic pathways, and treatment approaches tailored to people living with HIV.Apply for PA 16 426
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled ""High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.393.
- This funding opportunity was created on 2016-09-07.
- Applicants must submit their applications by 2019-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs): NIH PA-16-426 (R01) - HIV-Associated Malignancies
1) What is the funding opportunity number for this NIH grant?
The Funding Opportunity Number (FOA) is PA-16-426.
2) What type of grant mechanism is this opportunity using?
This opportunity uses the NIH R01 mechanism, which is a Research Project Grant intended for substantial, hypothesis-driven research projects.
3) What is the main focus of PA-16-426?
The FOA focuses on cancers that occur in people living with HIV or AIDS, with particular emphasis on non-AIDS-defining malignancies. The overall aim is to advance understanding of why these cancers occur, how they develop and progress, how to detect and diagnose them more effectively, and how to treat them in the context of HIV infection.
4) Why does this FOA emphasize non-AIDS-defining cancers?
The announcement notes that non-AIDS-defining cancers have become a leading cause of death among HIV-infected individuals. Because of that shifting disease burden, improving understanding and management of these malignancies is described as an urgent public health need.
5) Are AIDS-defining cancers included, or only non-AIDS-defining cancers?
Both can be included. The FOA supports research across non-AIDS-defining cancers and traditional AIDS-defining cancers, as long as the work directly advances knowledge relevant to malignancies in people with underlying HIV infection.
6) What kinds of research questions or topics does the FOA encourage?
The scope is broad and encourages projects addressing high or medium priority AIDS-related cancer questions. Examples mentioned include:
- Identifying etiologic factors and cofactors (for example, viral coinfections, behavioral or environmental exposures, and treatment-related influences)
- Clarifying immunopathogenesis, including how HIV-associated immune dysfunction and immune activation contribute to cancer initiation and progression
- Improving diagnosis and clinical characterization of malignancies in HIV-positive populations
- Studying consequences for patient outcomes and survivorship
7) What does "immunopathogenesis" mean in the context of this FOA?
In this announcement, immunopathogenesis refers to how HIV-related immune dysfunction and immune activation may contribute to the start of cancer (initiation) and how cancer worsens over time (progression) in people living with HIV.
8) What kinds of etiologic factors and cofactors are explicitly called out?
The FOA provides examples such as viral coinfections, behavioral or environmental exposures, and treatment-related influences that may affect cancer risk or outcomes in people with HIV.
9) Does this FOA support clinical and population-based research, or only lab-based studies?
Eligibility and the described scope indicate support for a wide range of research types, including biomedical, clinical, behavioral, and population-based research, as long as it advances knowledge about malignancies in people with HIV infection.
10) What stage(s) of cancer research does this FOA aim to support?
Based on the stated goals, the FOA supports research spanning cancer occurrence (why cancers happen), development and progression, improved detection and diagnosis, treatment in the context of HIV infection, and downstream consequences for patient outcomes and survivorship.
11) What is the funding instrument category?
The funding instrument is a discretionary grant, specifically an R01.
12) What does it mean that this is an R01 intended for substantial projects?
The description indicates the R01 is meant for multi-year research efforts with clearly defined aims, a strong scientific premise, and an approach appropriate to the complexity of studying cancer and HIV comorbidity. (The text does not list a specific project period or budget ceiling.)
13) Are award ceilings or the expected number of awards provided in the description?
No. The provided information explicitly notes that the source text does not provide an award ceiling or the expected number of awards.
14) What CFDA numbers are associated with this opportunity?
The program is listed under CFDA numbers 93.121 and 93.393.
15) What funding activity categories are associated with the FOA?
The FOA falls within the Education and Health funding activity categories.
16) Who is eligible to apply?
Eligibility is broad and includes a wide range of organizations capable of conducting relevant research. Eligible applicants include:
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments
- Tribal organizations that are not federally recognized
- Public housing authorities / Indian housing authorities
- Nonprofits with or without 501(c)(3) status (other than institutions of higher education)
- For-profit organizations (other than small businesses)
- Small businesses
- Other entities
17) Are minority-serving institutions and community-based organizations eligible?
Yes. The FOA specifically calls out additional eligible applicant types, including Alaska Native and Native Hawaiian Serving Institutions, AANAPISIs, Hispanic-serving Institutions, HBCUs, TCCUs, and faith-based or community-based organizations.
18) Are U.S. federal agencies eligible to apply?
Yes. The FOA lists eligible federal agencies among the additional eligible applicant types.
19) Are U.S. territories or possessions eligible?
Yes. The FOA explicitly includes U.S. territories or possessions as eligible applicant types.
20) Are non-U.S. (foreign) organizations eligible to apply?
Yes. The FOA explicitly includes non-U.S. entities (foreign organizations) as eligible applicants, signaling interest in diverse research settings and potentially international populations where HIV-associated cancer burdens are significant.
21) What does the FOA imply about collaboration or research settings?
The broad eligibility and explicit inclusion of non-U.S. entities suggest openness to diverse perspectives, varied research settings, and studies involving international populations or cross-regional collaborations, particularly where HIV-associated cancer burdens are significant.
22) What is the creation date for this FOA?
The creation date is 2016-09-07.
23) What is the original closing date for this FOA?
The original closing date is 2019-09-07.
24) What is the public health importance described in the FOA?
The FOA describes an urgent need to address the changing cancer landscape in people living with HIV, particularly because non-AIDS-defining malignancies have become a leading cause of death among HIV-infected individuals.
25) What kinds of outcomes is the FOA ultimately trying to improve?
Based on the stated goals, the FOA is aimed at generating evidence that can improve prevention strategies, diagnostic pathways, and treatment approaches tailored to people living with HIV, as well as improving understanding of outcomes and survivorship after cancer in HIV-positive populations.
Browse more opportunities from the same category: Education, Health
Next opportunity: BRAIN Initiative Fellows: Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)
Previous opportunity: Planning Grant for Emerging Epidemic Virus Research Training for West African Countries with Widespread Transmission of Ebola- Guinea, Liberia, and Sierra Leone (D71)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 426
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 426) also looked into and applied for these:
| Funding Opportunity |
|---|
| Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24) Apply for RFA DA 17 019 Funding Number: RFA DA 17 019 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Grand Opportunity in Medications Development for Substance-Use Disorders (U01) Apply for PAR 16 431 Funding Number: PAR 16 431 Agency: National Institutes of Health Category: Education, Health Funding Amount: $5,000,000 |
| Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01) Apply for PAR 16 430 Funding Number: PAR 16 430 Agency: National Institutes of Health Category: Education, Health Funding Amount: $3,000,000 |
| Health Promotion Among Racial and Ethnic Minority Males (R21) Apply for PA 16 432 Funding Number: PA 16 432 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Symptom Management in HIV-Infected Individuals with Comorbid Conditions (R01) Apply for PA 16 427 Funding Number: PA 16 427 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Symptom Management in HIV-Infected Individuals with Comorbid Conditions (R21) Apply for PA 16 429 Funding Number: PA 16 429 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Encouraging Appropriate Care Using Behavioral Economics through Electronic Health Records (R21/R33) Apply for RFA AG 17 013 Funding Number: RFA AG 17 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Drug Abuse Dissertation Research (R36) Apply for PA 16 443 Funding Number: PA 16 443 Agency: National Institutes of Health Category: Education, Health Funding Amount: $50,000 |
| Improving the HIV Pre-Exposure Prophylaxis (PrEP) Cascade (R34) Apply for RFA MH 17 361 Funding Number: RFA MH 17 361 Agency: National Institutes of Health Category: Education, Health Funding Amount: $225,000 |
| Improving the HIV Pre-Exposure Prophylaxis (PrEP) Cascade (R01) Apply for RFA MH 17 360 Funding Number: RFA MH 17 360 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Multi-Site Pilot and Feasibility Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R34) Apply for PAR 16 456 Funding Number: PAR 16 456 Agency: National Institutes of Health Category: Education, Health Funding Amount: $225,000 |
| Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01) Apply for PAR 16 455 Funding Number: PAR 16 455 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Collaborative Consortia for the Study of HIV Associated Cancers: U.S. and Low-and Middle-Income Country Partnerships (U54) Apply for RFA CA 16 018 Funding Number: RFA CA 16 018 Agency: National Institutes of Health Category: Education, Health Funding Amount: $600,000 |
| National Cancer Institute Program Project Applications (P01) Apply for PAR 16 457 Funding Number: PAR 16 457 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| International Research Scientist Development Award (IRSDA) (K01) Apply for PAR 17 002 Funding Number: PAR 17 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01) Apply for PAR 17 003 Funding Number: PAR 17 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Hepatitis C Virus (HCV) Advanced Molecular Detection in Support of Systems for Prevention, Treatment and Control of HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States (U24) Apply for RFA DA 17 023 Funding Number: RFA DA 17 023 Agency: National Institutes of Health Category: Education, Health Funding Amount: $370,000 |
| HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control (UG3/UH3) Apply for RFA DA 17 014 Funding Number: RFA DA 17 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Use of Technology to Enhance Patient Outcomes and Prevent Illness (R21) Apply for PA 17 009 Funding Number: PA 17 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Improving Individual and Family Outcomes through Continuity and Coordination of Care in Hospice (R21) Apply for PA 17 015 Funding Number: PA 17 015 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 426", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.